Key facts
- It has raised $27.5M; the latest was Accelerator/Incubator ($27.5M) in Sep 2025.
- Notable investors include Innovate UK, Mercia Ventures, Future Planet Capital, Maven Capital Partners UK, UK Innovation & Science Seed Fund — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Laverock Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Laverock Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Laverock Therapeutics
Developer of a gene silencing platform designed to engineer the next generation of programmable cell therapies. The company's platform facilitates cell therapies that are both programmable and adaptive - engineering novel functionality that responds to both intra- and extra-cellular environmental cues, enabling medical and biotechnology institutions to generate iPSC-derived products with improved efficacy, safety, and accessibility, solving many of the limitations with existing approaches.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2021
- Employees
- 39
- Website
- laverocktx.com/
- Ownership
- Privately Held (backing)
Laverock Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Laverock Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Laverock Therapeutics in its N-PORT filings yet. We sweep new filings monthly.